GlassScriptPhysician profile
Alexandra L Lyons
NPI 1235889205
$5,798.88
in general payments reported to CMS, 2019-2025
38 companies · $1,826 in 2025
The $1,826 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $447 · 2023: $1,461 · 2024: $2,065 · 2025: $1,826.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,334 · Entertainment: $17.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,333.95 |
| Entertainment | $17.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,103.10 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $749.89 | 2022-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $573.37 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $507.72 | 2022-2025 | |
| Novo Nordisk INC | $432.63 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $392.41 | 2022-2024 | Jardiance |
| Glaxosmithkline, LLC. | $232.42 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Eisai INC. | $190.89 | 2024-2025 | |
| Pfizer INC. | $155.51 | 2023-2025 | |
| Mylan Specialty L.P. | $147.05 | 2023-2024 | Yupelri |
| Viatris Specialty LLC | $139.63 | 2025 | Yupelri |
| Novartis Pharmaceuticals Corporation | $123.48 | 2022-2024 | |
| Amgen INC. | $117.02 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Dexcom, INC. | $105.50 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $102.74 | 2025 | Freestyle Libre 3, Prodigy |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $64.12 | 2022-2024 | Korlym |
| Shield Therapeutics INC | $64.05 | 2024-2025 | |
| Protega Pharmaceutials INC | $62.56 | 2025 | Roxybond |
| Merck Sharp & Dohme LLC | $54.22 | 2022-2025 | Verquvo, Capvaxive, M-M-R II |
| Inspire Medical Systems, INC. | $53.25 | 2024-2025 | Inspire |
| Boston Scientific Corporation | $40.96 | 2022-2025 | General - Vascular Intervention |
| Lundbeck LLC | $39.93 | 2025 | Rexulti |
| Astellas Pharma US INC | $31.41 | 2025 | Veozah |
| Indivior INC. | $26.57 | 2025 | Sublocade |
| Alkermes, INC. | $26.15 | 2023 | Vivitrol |
| Kowa Pharmaceuticals America, INC. | $25.52 | 2024 | Livalo |
| C2n Diagnostics, LLC | $24.83 | 2025 | Precivityad2 |
| Braeburn INC. | $24.25 | 2024 | Brixadi |
| Sumitomo Pharma America, INC. | $21.27 | 2025 | Gemtesa |
| Nestle Healthcare Nutrition INC. | $21.27 | 2023 | |
| Angiodynamics, INC. | $20.07 | 2025 | Auryon Laser System 100-120 Vac |
| Galderma Laboratories, L.P. | $19.75 | 2024 | |
| Phadia US INC. | $19.75 | 2023 | Immunocap |
| Sanofi-Aventis U.S. LLC | $19.12 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.97 | 2022 | |
| Optos, INC. | $17.89 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Ascensia Diabetes Care US INC. | $14.81 | 2024 | |
| Vanda Pharmaceuticals INC. | $14.80 | 2023 | Hetlioz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Lyons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.